Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Pharma & Biotech

US Risers & Fallers: Shaw communications, Arno, Cyberark, Qunar, Supervalu, DelMar

Shaw Communications is selling its media division to Corus for $2.65bn.

Below are some of the main news-driven share price changes as at 10:56 a.m. in New York.

RISERS

Shaw Communications (NYSE:SJR) surged 8.4% to US$17.81 after the Canadian media company struck a deal to sell off its broadcast subsidiary to Corus Entertainment (OTCMKTS:CJREF) for $2.65bn.

Arno Therapeutics (OTCQB:ARNI) jumped 17% to US$0.35 after the biopharma group brought in gross proceeds of around US$7.4mln to advance the clinical development of lead product onapristone for breast cancer and other tumours.

Cyberark Software (NASDAQ:CYBR) surged 18.6% to US$44.90 on the heels of a report that the Israel-based company is a potential acquisition target.

Qunar Cayman Islands (NASDAQ:QUNR) gained 13% to US$43.00 after Ctrip (NASDAQ:CTRP) reported a deal to make certain investments via a limited partnership capital contribution in several non-U.S. investment entities.

General Electric (NYSE:GE) inched up 0.2% to US$28.72. The U.S. engineering giant is to cut thousands of jobs in Europe following its deal to buy Alstom's power business for US£9.2bn last November.

FALLERS

Supervalu (NYSE:SVU) slumped 12% to US$5.29 after the supermarket chain reported a worse-than-expected 2.6% decline in third-quarter revenue.

DelMar Pharmaceuticals (OTCQX:DMPI) fell 1.1% to US$0.91. The Canadian clinical-stage drug development company entered into a collaboration to accelerate the clinical development of its lead anti-cancer candidate, VAL-083.

CSX (NASDAQ:CSX) fell 4% to US$22.75 after the transportation company reported weaker-than-anticipated revenue.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK